Hui-Zi Chen
Medical Oncology · Milwaukee, WINPI 1386082691
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,167 of the $41,073 with a category attached, or 88.1%. Jazz Pharmaceuticals Inc. accounts for 97.7% of it on its own, with 4 other manufacturers making up the rest. Among medical oncology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $1521.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$40K
- Exelixis Inc.$554
- AstraZeneca$250
- Foundation Medicine, Inc.$121
- Bayer$14
Across 141 payments — averaging $6685.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$443K
- Takeda Pharmaceuticals U.S.A., Inc.$316K
- Daiichi Sankyo Inc.$164K
- Mirati Therapeutics, Inc.$19K
- Eli Lilly$500
What the payments were for
- Consulting fees$1,5904%
- Speaking & faculty fees$36,16788%
- Travel & lodging$2,3996%
- Food & beverage$9032%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 21 | $40,134 |
| Exelixis Inc. | 2 | $554 |
| AstraZeneca | 2 | $250 |
| Foundation Medicine, Inc. | 1 | $121 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$39,975
- Cabometyx$554
- IMFINZI$125
- DATROWAY$125
- FOUNDATIONONE$121
- FOUNDATIONONE HEME$121
- FOUNDATIONONE CDX$121
- FOUNDATIONFOCUS$121
- FOUNDATIONONE LIQUID CDX$121
How this compares
$41,073 in reported general payments places this provider in the 90th percentile of 54 medical oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TibsovoIvosidenib | 11 | $299,889 |
| AlecensaAlectinib Hcl | 12 | $169,048 |
| OdomzoSonidegib Phosphate | 11 | $149,114 |
| MekinistTrametinib Dimethyl Sulfoxide | 16 | $146,756 |
| Dexamethasone | 41 | $637 |
| Olanzapine | 34 | $325 |
| Ondansetron Hcl | 24 | $235 |
| Levothyroxine Sodium | 15 | $112 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Milwaukee
- Alexandria PhanMilwaukee$260K
- Sumana DevataMilwaukee$296
- Stuart WongMilwaukee$33
- Zachary GraffMilwaukee$27
- Paul RitchMilwaukee$26
- Joshua LangMadison$114K
- Dustin DemingMadison$100K
- Kari WisinskiMadison$43K
- Justine BruceMadison$25K
- Francis CuevasFranklin$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.